SecBot SecBot
8-K ·Filed Nov 3, 2026

UTMD

UTAH MEDICAL PRODUCTS INC
NEUTRAL
Impact 2/10
Horizonweeks Processed13d 14h ago SEC0001096906-26-001664
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The dividend increase is small and routine. Monitor the next quarterly earnings filing for revenue and earnings trends, which are the primary drivers of UTMD's valuation.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$70.02
T+0 close · Nov 3, 2026 · via day close
Latest settled
+4.06%
T+5 · $72.86 · next T+20 in 15d
Vs SPY
+4.64%
α at T+5
Latest observation
+5.90%
T+9 · FF3 residual α
  1. T+0 · Nov 3 $70.02entry
  2. T+1 · 13d ago +3.43%α +1.78% · $72.42
  3. T+5 · 7d ago +4.06%α +4.64% · $72.86
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Utah Medical Products announced a 1.6% increase in its regular quarterly cash dividend to $0.315 per share, payable January 5, 2027 to holders of record December 17, 2026. The dividend increase is a routine capital allocation decision with no material financial data or change in fundamentals.

Key Facts

  • Quarterly cash dividend increased to $0.315 per share from the prior regular quarterly dividend
  • Dividend increase of 1.6% over the prior regular quarterly cash dividend
  • Payable on January 5, 2027 to shareholders of record on December 17, 2026
  • Company market cap is $213M with a normal daily move of 2.2%

Financial Impact

Quarterly dividend increased by 1.6% to $0.315 per share; no total payout amount stated

dividend per share

Risk Factors

  • Dividend increases do not offset declining fundamentals; no financial results were provided in this filing

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001096906-26-001664
Document: utmd_ex99z1.htm0001096906-26-001664
Document: 0001096906-26-001664-index-headers.html0001096906-26-001664
Document: 0001096906-26-001664-index.html0001096906-26-001664
Document: 0001096906-26-001664.txt0001096906-26-001664

Track record

11 reports on UTMD

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.45% at T+20 after the Apr 23, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 2/10 Viewing Entry $70.02 Now $72.36 +3.34% settles Dec 2
  2. Oct 29, 202618d ago Insider Buy Neutral 3/10 Entry $68.08 Now $72.36 +6.29% settles Nov 30
  3. Oct 29, 202618d ago SC TO-I/A Neutral 4/10 Entry $66.80 Now $72.36 +8.32% settles Nov 27
  4. Oct 22, 202625d ago 8-K Mixed 5/10 Entry $75.06 Now $72.36 −3.60% settles Nov 19
  5. Oct 5, 20266w ago SC TO-I/A Neutral 3/10 Entry $73.31 to $68.08 Now $72.36 −1.30% ▼ −7.14% −4.67% vs SPY
  6. Sep 25, 20267w ago SC TO-C Neutral 2/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
  7. Sep 24, 20267w ago SC TO-C Mixed 6/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
  8. Sep 23, 20267w ago SC TO-I Mixed 5/10 Entry $74.75 to $75.06 Now $72.36 −3.20% ▲ +0.41% +0.83% vs SPY
  9. Aug 31, 202611w ago 8-K Bullish 5/10 Entry $71.13 to $74.95 Now $72.36 +1.73% ▲ +5.37% +5.56% vs SPY
  10. Jul 23, 202616w ago 8-K Bearish 7/10 Entry $64.18 to $71.42 Now $72.36 −12.75% ▼ −11.28% −7.97% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 5h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026